Iprindole

Summary

Iprindole (CHEMBL126224) is an approved small molecule (ATC N06AA13); indicated across 1 condition including depressive disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: N06AA13
• Indications: 1 condition
• Chemistry: 284.4 Da · C19H28N2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL126224
Name	Iprindole
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	21722
ATC	N06AA13
Molecular formula	C19H28N2
Molecular weight	284.4
InChIKey	PLIGPBGDXASWPX-UHFFFAOYSA-N

SMILES: CN(C)CCCN1C2=C(CCCCCC2)C3=CC=CC=C31

IUPAC name: 3-(6,7,8,9,10,11-hexahydrocycloocta[b]indol-5-yl)-N,N-dimethylpropan-1-amine

Also known as: Galatur, Iprindol, Iprindole, NSC-169449, Pramindole, Prondol, Tertran, WY-3263, iprindole, IPRINDOLE

Patent coverage: 1,124 distinct patent families (4,398 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 4,352 (99%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 23 (assay-derived). Sample: Vasopressin V2 receptor, 5-hydroxytryptamine receptor 2B, Alpha-2A adrenergic receptor, Alpha-2C adrenergic receptor, Histamine H2 receptor, Alpha-2B adrenergic receptor, Muscarinic acetylcholine receptor M5, Muscarinic acetylcholine receptor M2, 5-hydroxytryptamine receptor 1A, D(2) dopamine receptor.

Bioactivity

ChEMBL activities: 23 potent at pChembl ≥ 5 of 29 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
HRH1	6.66	AC50	220	nM	CHEMBL_ACT_25211991
HTR2C	6.41	AC50	390	nM	CHEMBL_ACT_25131301
HTR2B	6.39	AC50	409.2	nM	CHEMBL_ACT_25163976
CHRM2	6.21	AC50	614	nM	CHEMBL_ACT_25195137
HRH2	6.15	AC50	704.7	nM	CHEMBL_ACT_25114322
HRH1	6.05	AC50	883.2	nM	CHEMBL_ACT_25116908
HTR2A	6.01	AC50	985.5	nM	CHEMBL_ACT_25173437
DRD3	5.82	AC50	1500	nM	CHEMBL_ACT_25193019
OPRK1	5.74	AC50	1828	nM	CHEMBL_ACT_25128963
ADRA1A	5.65	AC50	2254	nM	CHEMBL_ACT_25137627
HTR2B	5.58	AC50	2600	nM	CHEMBL_ACT_25227039
HTR6	5.49	AC50	3274	nM	CHEMBL_ACT_25118894
ADRA1A	5.32	AC50	4788	nM	CHEMBL_ACT_25138327
SLC6A2	5.31	AC50	4900	nM	CHEMBL_ACT_25144500
HTR5A	5.24	AC50	5804	nM	CHEMBL_ACT_25163897
DRD2	5.21	AC50	6200	nM	CHEMBL_ACT_25139816
HRH3	5.19	AC50	6500	nM	CHEMBL_ACT_25200178
HTR1A	5.14	AC50	7231	nM	CHEMBL_ACT_25164346
CHRM3	5.12	AC50	7600	nM	CHEMBL_ACT_25136196
CHRM5	5.08	AC50	8402	nM	CHEMBL_ACT_25137380
ADRA2B	5.08	AC50	8400	nM	CHEMBL_ACT_25143193
ADRA2C	5.05	AC50	9000	nM	CHEMBL_ACT_25147356
DRD4	5.01	AC50	9842	nM	CHEMBL_ACT_25127285

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
depressive disorder	4	MONDO:0002050	MONDO:0002009

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).